Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

July 7, 2003

Primary Completion Date

March 21, 2012

Study Completion Date

June 18, 2013

Conditions
Esophagus Cancer
Interventions
DRUG

Cisplatin

80mg/m2 IV day 1

RADIATION

Radiotherapy

35 Gy in 15 fractions

DRUG

5-Fluorouracil

800mg/m2/day IV days 1 - 4

Trial Locations (25)

1871

Liverpool Hospital, Liverpool

2031

Prince of Wales Hospital, Randwick

2069

Royal North Shore Hospital, Sydney

3128

Peter MacCallum - Box Hill Hospital, Box Hill

3165

Peter MacCallum - Moorrabbin, East Bentleigh

3220

Andrew Love Cancer Care Centre, Geelong Hospital, Geelong

4006

Premion - Wesley, Auchenflower

4029

Royal Brisbane Hospital, Herston

4101

Radiation Oncology - Mater Centre, South Brisbane

4102

Princess Alexandra Hospital, Woolloongabba

4710

Christchurch Hospital, Christchurch

4810

North Queensland Oncology Service, Townsville

5000

Royal Adelaide Hospital, Adelaide

6001

Royal Perth Hospital, Perth

7250

Launceston General Hospital, Launceston

8006

Peter MacCallum Cancer Centre, Melbourne

T6G 1Z2

Cross Cancer Centre, Edmonton

R3E 0V9

Cancer Care Manitoba Winnipeg, Winnipeg

E2L 4L2

Saint John Regional Hospital - Atlantic Health Sci, Saint John

B3H 1V7

Nova Scotia Cancer Centre, Halifax

K7L 5P9

Cancer Centre of Southeastern Ontario Kingston, Kingston

N2G 1G3

Grand River Cancer Centre, Kitchener

M5G 2M9

Princess Margaret Hospital, Toronto

G1R 2J6

Hotel-Dieu de Quebec, Québec

Unknown

Princess Royal Hospital, Hull

All Listed Sponsors
collaborator

National Health and Medical Research Council, Australia

OTHER

collaborator

Canadian Cancer Trials Group

NETWORK

lead

Trans Tasman Radiation Oncology Group

OTHER

NCT00193882 - Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia. | Biotech Hunter | Biotech Hunter